GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (NAS:ACCD) » Definitions » ROE %

Accolade (Accolade) ROE % : -6.82% (As of Feb. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Accolade ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Accolade's annualized net income for the quarter that ended in Feb. 2024 was $-30.0 Mil. Accolade's average Total Stockholders Equity over the quarter that ended in Feb. 2024 was $440.1 Mil. Therefore, Accolade's annualized ROE % for the quarter that ended in Feb. 2024 was -6.82%.

The historical rank and industry rank for Accolade's ROE % or its related term are showing as below:

ACCD' s ROE % Range Over the Past 10 Years
Min: -75.57   Med: -45.43   Max: -19.75
Current: -22.22

During the past 7 years, Accolade's highest ROE % was -19.75%. The lowest was -75.57%. And the median was -45.43%.

ACCD's ROE % is ranked worse than
78.27% of 612 companies
in the Healthcare Providers & Services industry
Industry Median: 4.035 vs ACCD: -22.22

Accolade ROE % Historical Data

The historical data trend for Accolade's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accolade ROE % Chart

Accolade Annual Data
Trend Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
ROE %
Get a 7-Day Free Trial - -75.57 -19.75 -69.14 -21.71

Accolade Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -25.37 -33.11 -29.45 -19.32 -6.82

Competitive Comparison of Accolade's ROE %

For the Health Information Services subindustry, Accolade's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accolade's ROE % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Accolade's ROE % distribution charts can be found below:

* The bar in red indicates where Accolade's ROE % falls into.



Accolade ROE % Calculation

Accolade's annualized ROE % for the fiscal year that ended in Feb. 2024 is calculated as

ROE %=Net Income (A: Feb. 2024 )/( (Total Stockholders Equity (A: Feb. 2023 )+Total Stockholders Equity (A: Feb. 2024 ))/ count )
=-99.805/( (473.786+445.465)/ 2 )
=-99.805/459.6255
=-21.71 %

Accolade's annualized ROE % for the quarter that ended in Feb. 2024 is calculated as

ROE %=Net Income (Q: Feb. 2024 )/( (Total Stockholders Equity (Q: Nov. 2023 )+Total Stockholders Equity (Q: Feb. 2024 ))/ count )
=-30.028/( (434.719+445.465)/ 2 )
=-30.028/440.092
=-6.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Feb. 2024) net income data. ROE % is displayed in the 30-year financial page.


Accolade  (NAS:ACCD) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=-30.028/440.092
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-30.028 / 499.324)*(499.324 / 786.811)*(786.811 / 440.092)
=Net Margin %*Asset Turnover*Equity Multiplier
=-6.01 %*0.6346*1.7878
=ROA %*Equity Multiplier
=-3.81 %*1.7878
=-6.82 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=-30.028/440.092
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-30.028 / -27.112) * (-27.112 / -31.588) * (-31.588 / 499.324) * (499.324 / 786.811) * (786.811 / 440.092)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.1076 * 0.8583 * -6.33 % * 0.6346 * 1.7878
=-6.82 %

Note: The net income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Accolade ROE % Related Terms

Thank you for viewing the detailed overview of Accolade's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Accolade (Accolade) Business Description

Traded in Other Exchanges
Address
1201 Third Avenue, Suite 1700, Seattle, WA, USA, 98101
Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. It generates revenue by providing personalized health guidance solutions to members.
Executives
Richard Eskew officer: EVP General Counsel C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Stephen H. Barnes officer: Chief Financial Officer C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Rajeev Singh director, officer: Chief Executive Officer 6222 185TH AVENUE NE, REDMOND WA 98052
Robert N Cavanaugh officer: President 1601 CLOVERFIELD BLVD., SUITE 620, SANTA MONICA CA 90404
Mchugh Colin officer: Chief Accounting Officer C/O ACCOLADE, INC., 660 W. GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Michael W Hilton officer: Chief Product Officer 6222 185TH AVE, REDMOND WA 98052
Peter S Klein director C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY, REDMOND WA 98052-6399
Cindy Kent director 7601 PENN AVENUE SOUTH, RICHFIELD MN 55418
Patricia L Wadors director C/O ALIGN TECHNOLOGY INC, 881 MARTIN AVE, SANTA CLARA CA 95050
Dawn G Lepore director 1425 BROADWAY PMB 41, SEATTLE WA 99122
Jeffrey D Jordan director 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
Jeffrey S Brodsky director C/O MORGAN STANLEY 1585 BROADWAY, NEW YORK NY 10036
Thomas J Neff director SPENCER STUART & ASSOCIATES, 277 PARK AVE, NEW YORK NY 10172
William H. Frist director 600 MONTGOMERY STREET, SAN FRANCISCO CA 94111

Accolade (Accolade) Headlines

From GuruFocus

Accolade Inc CFO Stephen Barnes Sells 640 Shares

By GuruFocus Research GuruFocus Editor 05-25-2023

Accolade Inc CEO Rajeev Singh Sells 1,578 Shares

By GuruFocus Research GuruFocus Editor 05-25-2023

Accolade to Webcast Analyst Day on May 8, 2023

By sperokesalga sperokesalga 04-24-2023

Accolade Announces Upcoming Investor Events

By sperokesalga sperokesalga 05-08-2023

Accolade to Announce Fiscal First Quarter 2024 Financial Results

By sperokesalga sperokesalga 06-13-2023

Accolade Inc CEO Rajeev Singh Sells 1,533 Shares

By GuruFocus Research 05-28-2023

Accolade Inc CEO Rajeev Singh Sells 7,622 Shares

By GuruFocus Research 06-15-2023